PharmaDeals Review
PharmaDeals Review (ISSN 1756-7874 online publication) is an electronic publication that augments the PharmaDeals v2 database to provide expert opinion and analyses. Unlike print publications, our expert editorial team publishes their articles immediately and continuously, ensuring you get vital deal information and analyses at the very earliest opportunity.
The three latest articles are listed below. View all the current Review articles using the Current Review Articles link to the right. Older Review articles (pdf format only) are available in the archive.
Eli Lilly Wins the ImClone Prize
2008-10-06
Eli Lilly has become the proud owner of ImClone, successfully outbidding Bristol-Myers Squibb (BMS) and paying nearly US$2 B more than BMS’ original offer in the process. ImClone fitted neatly into both companies’ strategies, though the size of this acquisition shows that Eli Lilly was the more eager out of the two. ImClone does, however, come with some strings attached.
Genentech and Roche Sign Deal for GlycArt’s Anticancer Antibody Therapy
2008-10-03
Genentech and Roche have entered into a new deal this month, although not the anticipated acquisition of the biotech by the Swiss giant. Instead the companies have formed a collaboration with GlycArt for the development of its antibody for the potential treatment of CD20-positive B-cell malignancies.
Merck Heads Back to India for More Anti-Infective Programmes
2008-09-30
Merck continues to look at countries with emerging markets and promising drug discovery capabilities in its bid to find good drug candidates to populate its pipeline. Its latest agreement with Chennai, India-based Orchid Chemicals and Pharmaceuticals is for the discovery and development of anti-infectives.
PharmaDeals Review features:
PharmaDeals analyses specific deals and examines trends and developments within deal making in different technology and therapy areas. It also assess data from the PharmaDeals v2 database, as well as many other sources of information and the in-house knowledge base available to our expert team of writers.
- Deal trackers articles where late phase and recently launched products are explored from the perspective of the deals done to bring them through development, offering insight into the complex alliance history of individual drugs
- Deal analysis and opinion from our expert team of writers
- Business commentary – The Publisher and CEO Dr Fintan Walton comments on topical industry issues and how they may impact on deal making
- Feature articles from the industry’s thought leaders offering in-depth analysis of the key developments within deal making
- Global companies' deal watch
- Conference calendar – specially selected conferences
- Yearly analysis: Summary of the year and comment prospective, future trends
In addition, your subscription includes the entire PharmaDeals Review Article Archive – hundreds of articles all links to specific deals recorded in the PharmaDeals v2 database
Subscribers to PharmaDeals v2, receive PharmaDeals Review at no additional cost.
Review and Analysis, Navigation
Bookmarks
Bookmark PharmaDeals through one of these social networks.
